2018 Peritonitis Drug Development- Pipeline Analysis Report
Inflammation of pertonitis, the lining of inner wall of abdomen is referred to as Peritonitis condition. It is an urgent medical condition and is highly infectious, with an estimated 10% mortality rates.
Over 15 companies and universities are focusing on developing treatment options for Peritonitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Peritonitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Peritonitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Peritonitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Over 15 companies and universities are focusing on developing treatment options for Peritonitis.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Peritonitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Peritonitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Peritonitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 PERITONITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Peritonitis Pipeline Snapshot
2.3 Peritonitis Pipeline by Phase
2.4 Peritonitis Pipeline by Company
2.5 Peritonitis Pipeline by Mechanism of Action
3 PERITONITIS- COMPANY WISE PIPELINE ANALYSIS
Adenium Biotech
Atox Bio Ltd
Melinta Therapeutics
Reponex Pharmaceuticals
Sirtris
SynAct Pharma AB
Zytoprotec
4 PERITONITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PERITONITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 PERITONITIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Peritonitis Pipeline Snapshot
2.3 Peritonitis Pipeline by Phase
2.4 Peritonitis Pipeline by Company
2.5 Peritonitis Pipeline by Mechanism of Action
3 PERITONITIS- COMPANY WISE PIPELINE ANALYSIS
Adenium Biotech
Atox Bio Ltd
Melinta Therapeutics
Reponex Pharmaceuticals
Sirtris
SynAct Pharma AB
Zytoprotec
4 PERITONITIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN PERITONITIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Peritonitis Pipeline by Phase, H1- 2018
Figure 2: Peritonitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Peritonitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Peritonitis Pipeline by Phase, H1- 2018
Figure 2: Peritonitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Peritonitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Peritonitis Pipeline by Phase, H1- 2018
Table 2: Peritonitis Pipeline by Companies, H1- 2018
Table 3: Peritonitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Adenium Biotech Peritonitis pipeline, May 2018
Table 5: Atox Bio Ltd Peritonitis pipeline, May 2018
Table 6: Melinta Therapeutics Peritonitis pipeline, May 2018
Table 7: Reponex Pharmaceuticals Peritonitis pipeline, May 2018
Table 8: Sirtris Peritonitis pipeline, May 2018
Table 9: SynAct Pharma AB Peritonitis pipeline, May 2018
Table 10: Zytoprotec Peritonitis pipeline, May 2018
Table 1: Peritonitis Pipeline by Phase, H1- 2018
Table 2: Peritonitis Pipeline by Companies, H1- 2018
Table 3: Peritonitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Adenium Biotech Peritonitis pipeline, May 2018
Table 5: Atox Bio Ltd Peritonitis pipeline, May 2018
Table 6: Melinta Therapeutics Peritonitis pipeline, May 2018
Table 7: Reponex Pharmaceuticals Peritonitis pipeline, May 2018
Table 8: Sirtris Peritonitis pipeline, May 2018
Table 9: SynAct Pharma AB Peritonitis pipeline, May 2018
Table 10: Zytoprotec Peritonitis pipeline, May 2018
